SkylineDx Launches New Global Corporate Website

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 20, 2024: – SkylineDx, an innovative molecular diagnostics company, proudly announces the launch of its new corporate website, a testament to the company’s commitment to innovation and excellence. Designed to provide more visibility on the great progress the team at SkylineDx is making on its commitment to realize molecular diagnostics and personalized care pathways, this new website  presents our research and development activities as well as informs on the clinical solutions we have introduced to clinical practice.

“We are thrilled to present the new corporate website to the world,” said Dharminder Chahal, CEO of SkylineDx. “This project signifies a pivotal moment in our journey, as we aim to showcase our strengths, achievements, and unwavering dedication to improving patient outcomes through advanced molecular diagnostics. The website serves as a powerful platform to engage with our stakeholders, providing a comprehensive view of our capabilities, achievements, and vision for the future.”

Embracing a unified global approach, the website provides a comprehensive view of SkylineDx’s operations with dedicated pages and information for medical professionals and researchers. 

For the first time, SkylineDx provides detailed descriptions of its pipeline programs, offering stakeholders a deeper understanding of the company’s pioneering research and development initiatives.

The launch of the new corporate website underscores SkylineDx’s commitment to excellence, innovation, and customer-centricity. To explore the website and learn more about SkylineDx’s groundbreaking work, visit

About SkylineDx 

SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology and inflammatory diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient’s response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam. the Netherlands, complemented by a U.S. base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), April 5, 2024: — SkylineDx is pleased to announce two forthcoming scientific publications at the European Association for Dermato-Oncology congress, April 4-6, 2024. These publications...

ROTTERDAM (the Netherlands), SAN DIEGO (USA), March 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients was independently validated in a Swedish (European) cohort, where it could reduce approximately a...

ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 8, 2024: — SkylineDx, an innovative molecular diagnostics company, announces the forthcoming presentation of an impactful poster by Dr. Yu from University Hospital Cleveland Medical...

Select your mailing list